Compare MDXG & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDXG | CRMD |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 876.7M |
| IPO Year | N/A | 2010 |
| Metric | MDXG | CRMD |
|---|---|---|
| Price | $6.94 | $10.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $12.00 | ★ $17.43 |
| AVG Volume (30 Days) | 777.2K | ★ 3.1M |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.27 | ★ 2.25 |
| Revenue | ★ $393,442,000.00 | $214,303,672.00 |
| Revenue This Year | $19.13 | $627.89 |
| Revenue Next Year | $2.11 | $40.95 |
| P/E Ratio | $25.66 | ★ $4.69 |
| Revenue Growth | 14.77 | ★ 1647.67 |
| 52 Week Low | $5.79 | $5.60 |
| 52 Week High | $10.14 | $17.43 |
| Indicator | MDXG | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 51.56 |
| Support Level | $6.62 | $9.20 |
| Resistance Level | $6.97 | $9.88 |
| Average True Range (ATR) | 0.26 | 0.51 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 50.63 | 67.76 |
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.